Advances and challenges in the development and production of effective plant-based influenza vaccines (Q38285425)

1 September 2017

1 reference

title

Advances and challenges in the development and production of effective plant-based influenza vaccines (English)

1 reference

1 September 2017

1

Vidadi Yusibov

1 reference

1 September 2017

Natasha Kushnir

2

1 reference

PubMed ID

25487788

1 September 2017

Stephen J Streatfield

series ordinal

3

1 reference

1 September 2017

9 December 2014

1 reference

Expert Review of Vaccines

1 September 2017

1 reference

1 September 2017

14

1 reference

1 September 2017

4

1 reference

1 September 2017

519-535

1 reference

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

1 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Emergence of a novel swine-origin influenza A (H1N1) virus in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Response to a monovalent 2009 influenza A (H1N1) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Influenza vaccines: the good, the bad, and the eggs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Application of recombinant DNA techniques in the development of viral vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Influenza M2 proton channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Architecture of ribonucleoprotein complexes in influenza A virus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Influenza virus matrix protein is the major driving force in virus budding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Structural basis of influenza virus neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

T-helper 1 cells elicited by H5N1 vaccination predict seroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Cytotoxic T-cell immunity to influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Correlates of protection to influenza virus, where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Production of recombinant proteins by yeast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Bacterial expression systems for recombinant protein production: E. coli and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Insect cells as factories for biomanufacturing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Mammalian cell protein expression for biopharmaceutical production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

N-glycosylation engineering of biopharmaceutical expression systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Key issues in the selection of an expression system for vaccine antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Versatile virus-like particle carrier for epitope based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Yeast expressed recombinant Hemagglutinin protein of novel H1N1 elicits neutralising antibodies in rabbits and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Recombinant haemagglutinin protein of highly pathogenic avian influenza A (H5N1) virus expressed in Pichia pastoris elicits a neutralizing antibody response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Development of stable influenza vaccine powder formulations: challenges and possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Formulation and immunogenicity of a potential multivalent type III secretion system-based protein vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

A systematic approach toward stabilization of CagL, a protein antigen from Helicobacter pylori that is a candidate subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Plants as bioreactors for the production of vaccine antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Plant-made vaccines for humans and animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

21 January 2018

Plants as biofactories

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Plants as bioreactors: Recent developments and emerging opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Transgene silencing by the host genome defense: implications for the evolution of epigenetic control mechanisms in plants and vertebrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Chloroplast vector systems for biotechnology applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Plant-made vaccine antigens and biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Approaches to achieve high-level heterologous protein production in plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Hybrid viral vectors for vaccine and antibody production in plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

The use of plants for the production of therapeutic human peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

21 January 2018

2012 FDA drug approvals

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Magnifection--a new platform for expressing recombinant vaccines in plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Extremely high-level and rapid transient protein production in plants without the use of viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

A launch vector for the production of vaccine antigens in plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

A plant-produced plague vaccine candidate confers protection to monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

A plant-produced influenza subunit vaccine protects ferrets against virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Plant-expressed HA as a seasonal influenza vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Immunogenicity of hemagglutinin from A/Bar-headed Goose/Qinghai/1A/05 and A/Anhui/1/05 strains of H5N1 influenza viruses produced in Nicotiana benthamiana plants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

GMP issues for recombinant plant-derived pharmaceutical proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Commercial aspects of pharmaceutical protein production in plants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Automated production of plant-based vaccines and pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in health

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Third International Conference on Plant-Based Vaccines and Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

A plant-based system for rapid production of influenza vaccine antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Comparative characterization of the glycosylation profiles of an influenza hemagglutinin produced in plant and insect hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

A novel influenza A (H1N1) vaccine in various age groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Structural basis of immune recognition of influenza virus hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Molecular and immunological characterization of soluble aggregated A/Victoria/3/75 (H3N2) influenza haemagglutinin expressed in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

A conserved trimerization motif controls the topology of short coiled coils

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

A plant-produced H1N1 trimeric hemagglutinin protects mice from a lethal influenza virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Virus-like particles: passport to immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Virus-like particles: flexible platforms for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Induction of long-term protective immune responses by influenza H5N1 virus-like particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Virus-like particles as universal influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

M2e-based universal influenza A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Role of plant virus movement proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

Setting up a platform for plant-based influenza virus vaccine production in South Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.989988

10.1586/14760584.2015.989988

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25487788